Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.

Large and comprehensive genomic surveys of head and neck squamous cell carcinomas (HNSCC) are now greatly increasing our understanding of the diversity of this disease and the key genomic changes that drive these tumors. The results from these studies are beginning to inform the introduction of novel therapies for patients with HNSCCs. Here, we review some of the key findings from recent genomic studies of head and neck cancers, including the most comprehensive study to date from The Cancer Genome Atlas Network.

[1]  Petar Stojanov,et al.  Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas , 2014, Clinical Cancer Research.

[2]  J. Tabernero,et al.  Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. , 2014 .

[3]  M. Shipp,et al.  PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.

[4]  R. Gibbs,et al.  Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. , 2013, Cancer discovery.

[5]  R. Gibbs,et al.  Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers , 2014, Clinical Cancer Research.

[6]  E. Vokes,et al.  EGFR-directed treatments in SCCHN. , 2013, The Lancet. Oncology.

[7]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[8]  T. Ried,et al.  Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability , 2014, Genome research.

[9]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression , 2004 .

[10]  M. Meyerson,et al.  Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke , 2015, Head & neck.

[11]  J. Mesirov,et al.  Integrative radiogenomic profiling of squamous cell lung cancer. , 2013, Cancer research.

[12]  Amy Y. Chen,et al.  Head and neck carcinoma in the United States , 2012, Cancer.

[13]  Chandra Sekhar Pedamallu,et al.  Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. , 2013, Cancer research.

[14]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. , 2004, Cancer cell.

[15]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[16]  M. Hidalgo,et al.  Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. , 2014 .

[17]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[18]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[20]  Christopher R. Cabanski,et al.  Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes , 2013, PloS one.

[21]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[22]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[23]  P J F Snijders,et al.  Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus , 2006, Oncogene.

[24]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[25]  Chandra Sekhar Pedamallu,et al.  Characterization of HPV and host genome interactions in primary head and neck cancers , 2014, Proceedings of the National Academy of Sciences.

[26]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[27]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[28]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[29]  E. Cohen.  Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Dolled-Filhart,et al.  A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. , 2014 .

[31]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[32]  Trevor J Pugh,et al.  Landscape of genomic alterations in cervical carcinomas , 2013, Nature.

[33]  Amy Y. Chen,et al.  Longitudinal oncology registry of head and neck carcinoma (LORHAN) , 2011, Cancer.

[34]  J. Bonventre,et al.  Abstract 5195: Kidney injury molecule-1: a novel therapeutic target in renal cell carcinoma. , 2013 .

[35]  G. Reifenberger,et al.  Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. , 2014 .

[36]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[37]  Simion I. Chiosea,et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.

[38]  V. Grégoire,et al.  Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Christine H Chung,et al.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.